Which hedge funds own XLRN? ACCELERON PHARMA INC, Q2 2026 13F holders
0 tracked hedge funds disclosed a position in XLRN (ACCELERON PHARMA INC) in their Q2 2026 13F filings, worth $0 in total.
- 0
- Holders
- 0
- New this quarter
- 0
- Exited this quarter
- $0
- Combined value
- –
- Share of managers holding
Holders, Q2 2026
Ownership over time
By quarter
| Quarter | Holders | Managers filing | Share holding | Combined value |
|---|---|---|---|---|
| Q4 2021 | 0 | 74 | 0.0% | $0 |
| Q3 2021 | 8 | 71 | 11.3% | $917m |
| Q2 2021 | 6 | 71 | 8.5% | $652m |
| Q1 2021 | 5 | 70 | 7.1% | $748m |
| Q4 2020 | 5 | 71 | 7.0% | $691m |
| Q3 2020 | 5 | 68 | 7.4% | $599m |
| Q2 2020 | 5 | 68 | 7.4% | $403m |
| Q1 2020 | 5 | 68 | 7.4% | $383m |
| Q4 2019 | 3 | 67 | 4.5% | $151m |
| Q3 2019 | 4 | 60 | 6.7% | $135m |
| Q2 2019 | 3 | 60 | 5.0% | $168m |
| Q1 2019 | 3 | 60 | 5.0% | $173m |
| Q4 2018 | 3 | 60 | 5.0% | $140m |
| Q3 2018 | 3 | 59 | 5.1% | $122m |
| Q2 2018 | 1 | 59 | 1.7% | $68.0m |
| Q1 2018 | 1 | 59 | 1.7% | $54.8m |
| Q4 2017 | 2 | 59 | 3.4% | $46.5m |
| Q3 2017 | 3 | 56 | 5.4% | $41.6m |
| Q2 2017 | 1 | 56 | 1.8% | $389k |
| Q1 2017 | 2 | 56 | 3.6% | $5.1m |
| Q4 2016 | 2 | 56 | 3.6% | $1.4m |
| Q3 2016 | 3 | 52 | 5.8% | $13.9m |
| Q2 2016 | 1 | 52 | 1.9% | $480k |
| Q1 2016 | 1 | 52 | 1.9% | $293k |
| Q4 2015 | 1 | 52 | 1.9% | $216k |
| Q3 2015 | 2 | 52 | 3.8% | $2.6m |
| Q2 2015 | 2 | 52 | 3.8% | $8.7m |
| Q1 2015 | 1 | 52 | 1.9% | $3.1m |
| Q4 2014 | 1 | 52 | 1.9% | $3.1m |
Who discovered XLRN first?
Earliest meaningful positions among the 13 tracked managers seen opening XLRN since Q4 2014.
| Farallon Capital Management, L.L.C. | Q3 2017 | 0.4% | Exited by Q4 2021 | +105% |
| Alkeon Capital Management LLC | Q3 2018 | 0.2% | Exited by Q4 2021 | +100% |
| Avidity Partners Management LP | Q1 2020 | 2.1% | Exited by Q4 2021 | +92% |
Stock since is the split-adjusted change in the quarter-end price, excluding dividends, from the first reported quarter: the price the 13F filings themselves imply (value ÷ shares), blank across any gap that cannot be accounted for. It describes the stock, not the return any manager earned.